• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia -- Final Results of a Prospective Phase 2 Study
CONCLUSION:Pomalidomide with prednisone is safe therapy with good anti-anemia activity in patients with MF. It could lead to transfusion independence in one third of patients for a median duration of about 30 months. ClinicalTrials.gov Identifier: NCT00946270.Table 1.DisclosuresDaver: Alexion: Consultancy; ImmunoGen: Consultancy; Pfizer: Research Funding; Karyopharm: Research Funding; Otsuka: Consultancy; Novartis: Consultancy; ARIAD: Research Funding; Incyte: Consultancy; Pfizer: Consultancy; BMS: Research Funding; Sunesis: Research Funding; Daiichi-Sankyo: Research Funding; Sunesis: Consultancy; Kiromic: Research Funding...
Source: Blood - November 21, 2018 Category: Hematology Authors: Masarova, L., Daver, N. G., Kadia, T. M., Pemmaraju, N., Jabbour, E. J., Zhou, L., Pierce, S. A., Cortes, J. E., Kantarjian, H. M., Verstovsek, S. Tags: 634. Myeloproliferative Syndromes: Clinical: Poster I Source Type: research

A Rare Case of Churg Strauss Syndrome Associated with Cervical Spine and Brain Involvement (P4.037)
CONCLUSIONS:This patient meets four major criteria for diagnosis of CSS ( presence of sinusitis, histologic evidence of eosinophilic vasculitis, peripheral eosinophilia and pulmonary infiltrates). CSS associated with spine vasculitis is a rare but potentially serious clinical entity that may also lead to vascular/granulomatous compressive complications leading to permanent neurological damage. This may be only the second case of spinal cord non-hemorrhagic myelitis associated with CSS.Study Supported by:Disclosure: Dr. Mittal has nothing to disclose. Dr. Acsadi has received personal compensation for activities with Talecri...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Mittal, S., Acsadi, A., Cruz, L., Aglio, T., Ek, K., Lakshminarayanan, S., Logee, K. Tags: General Neurology III Source Type: research

Rapidly Fatal Internal Carotid Artery Mycotic Aneurysm Rupture in a Rheumatoid Patient Taking a TNF-α Inhibitor: Case Report and Literature Review
Conclusions Although fungal mycotic aneurysms of the ICA are rare, their incidence may increase with the expanded use of immunosuppressive medications. Patients with rheumatoid arthritis who take potent immunosuppression regimens may be prime candidates for mycotic aneurysms because they often have two favoring conditions: atherosclerosis and immunosuppression. These ICA aneurysms carry a high mortality rate, so early diagnosis and aggressive therapy, potentially by endovascular trapping/vessel occlusion coupled with long-term antifungal therapy, is essential.[...]Georg Thieme Verlag KG Stuttgart · New YorkArticle in Th...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - July 21, 2014 Category: Neurosurgery Authors: Bowers, Christian A.Saad, DanyClegg, Daniel O.Ng, PerryClayton, FredericHaydoura, SouhaSchmidt, Richard H. Tags: Case Report Source Type: research

Primary Angiitis of the Central Nervous System (PACNS) Presenting with Intracerebral Hemorrhage (P2.293)
Conclusion: Primary CNS vasculitis should be suspected even in patients presenting initially with intracerebral hemorrhage in association with only moderate headaches.Disclosure: Dr. Alkhalifah has nothing to disclose. Dr. Fayad has received research support from the National Institute of Neurological Disorders and Stroke and St. Jude Medical. Dr. Omojola has nothing to disclose. Dr. Hearth-Holmes has nothing to disclose. Dr. McComb has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Alkhalifah, M., Fayad, P., Omojola, M., Hearth-Holmes, M., McComb, R. Tags: Cerebrovascular Disease and Interventional Neurology: Inflammation and Immunology Source Type: research

Primary Angiitis of the Central Nervous System (PACNS) presenting with intracerebral hemorrhage (ICH): three cases associated with chronic use of over-the-counter vasoconstrictive drugs (P7.128)
CONCLUSIONS: While the FDA withdrew phenylpropanolamine due to its association with ICH, other vasoconstrictive agents remain ingredients of nasal decongestants/diet pills. These may induce chronic vasoconstriction leading to secondary inflammation and arterial rupture, culminating in atypical PACNS presentations such as multifocal ICH or ICH with acute infarcts (patients 1,2).Disclosure: Dr. Jha has nothing to disclose. Dr. George has nothing to disclose. Dr. Singhal has received personal compensation for activities as a medicolegal expert witness. Dr. Singhal's spouse holds stock and/or stock options in Biogen Idec.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jha, R., George, J., Singhal, A. Tags: Cerebrovascular Disease and Interventional Neurology: Stroke in Young Source Type: research

Vasculitis associated with adenosine deaminase 2 deficiency: at the crossroads between Beh çet's disease and autoinflammation. A viewpoint
Reumatismo. 2023 Sep 18;75(3). doi: 10.4081/reumatismo.2023.1578.ABSTRACTAdenosine deaminase 2 deficiency (DADA2) is a rare monogenic vasculopathy caused by loss-of-function homozygous or compound heterozygous mutations in ADA2, formerly CECR1 (cat eye syndrome chromosome region 1) gene. The DADA2 phenotype is widely heterogeneous, and patients may present with fever, weight loss, livedo reticularis/racemosa, digital ischemia, cutaneous ulceration, peripheral neuropathy, abdominal pain, bowel perforation, and portal or nephrogenic hypertension. More specific manifestations include early-onset ischemic or hemorrhagic stroke...
Source: Reumatismo - September 18, 2023 Category: Rheumatology Authors: A Colangelo F Tromby G Cafaro R Gerli E Bartoloni C Perricone Source Type: research